Study of Iptacopan Treatment for C3G Patients in Spain
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tracks adults with C3G (a rare kidney disease where the immune system damages the filtering units) who have already received iptacopan (a new medicine) through an early access program in Spain. Researchers want to understand how well this treatment works and its safety in real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of C3G (complement 3 glomerulopathy) from a kidney biopsy
- You received at least one dose of iptacopan through Spain's early access program between October 2020 and June 2025
- You took iptacopan specifically for C3G, not for another condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called iptacopan for people with a kidney condition called C3G. It looks at how the disease progresses in those who have taken or are currently taking iptacopan.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
This study looks at how well pegcetacoplan works and how safe it is for people with two rare kidney diseases, called C3G and IC-MPGN. It will help doctors understand how the medicine helps patients in real life, outside of a strict clinical trial.
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Hear when a new Complement 3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.